Mission Statement

Our company is dedicated to advancing the health and well-being of individuals affected by radiation exposure, be it through a nuclear strike, accident or during cancer treatment.

We strive to develop innovative medical countermeasures that can protect against the harmful effects of radiation and provide supportive care. Our mission is to empower patients, healthcare professionals, and emergency responders with effective solutions to mitigate the impact of these complex health and clinical challenges related to radiation-induced toxicity. We are committed to scientific excellence, collaboration, and a patient-centered approach to drive scientific progress and make a positive impact on society.

Who we are 

Myelo Therapeutics GmbH is a small biotech company developing innovative treatments to mitigate Acute Radiation Syndrome, and in the field of Cancer supportive care. We manage our development program by combining our in-house research with coordination of contract research organizations and collaboration with leading universities around the world.

In 2023, Myelo Therapeutics GmbH became one of Eckert und Ziegler Strahlen- und Medizintechnik AG fully owned pharmaceutical development companies. Eckert & Ziegler is a global leader in the development and production of isotope technology components for medical, scientific, and measurement technology applications. Our research is supported by the prestigious US National Institute of Health and the European Commission's European Defence Fund.